MedTrace Logo

The Effects of Lovaza® in Acute Myocardial Infarction

NCT01155336 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2017-11-06

Study results available
· View outcomes & findings →

Summary

This study will explore the safety and effectiveness of adding Lovaza® to the therapeutic program utilized internationally for the treatment of individuals with acute coronary syndromes.

Conditions

Interventions

DRUG

Lovaza®

Lovaza® is prescription grade EPA+DHA fish oil supplement.

DRUG

The placebo contained 1 gram of corn oil in each capsule.

Placebo Pill

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Albany College of Pharmacy and Health Sciences

    collaborator OTHER

  • University of Rochester

    lead OTHER

Principal Investigators

  • Robert Block, MD, MPH · University or Rochester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01155336 on ClinicalTrials.gov